{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:46:05Z","timestamp":1789854365483,"version":"4.0.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jaac.2015.06.015","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:47:49Z","timestamp":1436316469000},"page":"718-727.e3","source":"Crossref","is-referenced-by-count":36,"title":["Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics"],"prefix":"10.1016","volume":"54","author":[{"given":"Maren","family":"Carbon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Al-Jadiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Azzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2015.06.015_bib1","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2015.06.015_bib2","doi-asserted-by":"crossref","first-page":"e07","DOI":"10.4088\/JCP.9101tx3c","article-title":"Addressing side effects from antipsychotic treatment in schizophrenia","volume":"72","author":"Kane","year":"2011","journal-title":"The J Clin Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/cap.2013.0007","article-title":"Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics","volume":"23","author":"Stentebjerg-Olesen","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib4","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/070674379804300608","article-title":"Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms","volume":"43","author":"Lewis","year":"1998","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib5","first-page":"CD009582","article-title":"Atypical antipsychotics for psychosis in adolescents","volume":"10","author":"Kumar","year":"2013","journal-title":"Cochrane Database System Rev"},{"issue":"8","key":"10.1016\/j.jaac.2015.06.015_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/11592020-000000000-00000","article-title":"Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Pringsheim","year":"2011","journal-title":"Drug Safety"},{"key":"10.1016\/j.jaac.2015.06.015_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","article-title":"Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons","volume":"21","author":"Fraguas","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib8","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2015.06.015_bib9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A\u00a0multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/cap.2008.0111","article-title":"An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder","volume":"19","author":"Findling","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/10445460152595568","article-title":"A\u00a0prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder","volume":"11","author":"Frazier","year":"2001","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/cap.2006.16.393","article-title":"An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia","volume":"16","author":"Mozes","year":"2006","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/104454603321666216","article-title":"Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial","volume":"13","author":"McConville","year":"2003","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","article-title":"Olanzapine compared to quetiapine in adolescents with a first psychotic episode","volume":"18","author":"Arango","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1399-5618.2009.00750.x","article-title":"Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study","volume":"11","author":"Haas","year":"2009","journal-title":"Bipolar disorders"},{"key":"10.1016\/j.jaac.2015.06.015_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1192\/bjp.bp.107.046177","article-title":"Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study","volume":"194","author":"Haas","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism","volume":"15","author":"Aman","year":"2005","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/cap.2012.0068","article-title":"Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study","volume":"23","author":"Findling","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/cap.2008.008","article-title":"Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder","volume":"18","author":"DelBello","year":"2008","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib20","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study","volume":"165","author":"Sikich","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1345\/aph.1M643","article-title":"Anticholinergic use in children and adolescents after initiation of antipsychotic therapy","volume":"44","author":"Hong","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaac.2015.06.015_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A\u00a0rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.jaac.2015.06.015_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A\u00a0rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib25","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaac.2015.06.015_bib26","series-title":"ECDEU Assessment Manual for Psychopharmacology (Revised)","author":"Guy","year":"1976"},{"key":"10.1016\/j.jaac.2015.06.015_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2011.0092","article-title":"Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial","volume":"22","author":"Findling","year":"2012","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.08m03538","article-title":"The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials","volume":"70","author":"Kryzhanovskaya","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib29","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","article-title":"Olanzapine versus placebo in the treatment of adolescents with bipolar mania","volume":"164","author":"Tohen","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib30","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.4088\/JCP.11m07424","article-title":"Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial","volume":"74","author":"Pathak","year":"2013","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib31","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1089\/cap.2012.0092","article-title":"Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study","volume":"23","author":"Findling","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacology"},{"key":"10.1016\/j.jaac.2015.06.015_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4088\/JCP.v69n0120","article-title":"A\u00a0randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit\/hyperactivity disorder","volume":"69","author":"Findling","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib33","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A\u00a0placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib34","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A\u00a06-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia","volume":"19","author":"Haas","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/cap.2012.0029","article-title":"Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder","volume":"23","author":"Findling","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bdi.12042","article-title":"Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study","volume":"15","author":"Findling","year":"2013","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jaac.2015.06.015_bib37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2007.0138","article-title":"Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach","volume":"18","author":"Castro-Fornieles","year":"2008","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/YIC.0b013e3283320511","article-title":"A\u00a0trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents","volume":"25","author":"Swadi","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","article-title":"Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents","volume":"15","author":"Correll","year":"2006","journal-title":"Child Adolesc Psychiatr Clin North Am"},{"key":"10.1016\/j.jaac.2015.06.015_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes","volume":"47","author":"Correll","year":"2008","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1399-5618.2010.00798.x","article-title":"Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials","volume":"12","author":"Correll","year":"2010","journal-title":"Bipolar Disord"},{"issue":"1","key":"10.1016\/j.jaac.2015.06.015_bib42","first-page":"CD006918","article-title":"Risperidone versus placebo for schizophrenia","author":"Rattehalli","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jaac.2015.06.015_bib43","first-page":"CD000967","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jaac.2015.06.015_bib44","first-page":"CD001359","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaac.2015.06.015_bib45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaac.2015.06.015_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/104454603322572651","article-title":"Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study","volume":"13","author":"Zalsman","year":"2003","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib48","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of\u00a0antipsychotics in a randomised trial","volume":"193","author":"Miller","year":"2008","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaac.2015.06.015_bib49","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Move Disord"},{"key":"10.1016\/j.jaac.2015.06.015_bib50","first-page":"1760","article-title":"Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP\/SPECT and fluorine-18-FDOPA\/PET","volume":"37","author":"Ishikawa","year":"1996","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jaac.2015.06.015_bib51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/JCP.0b013e3182a6a2e3","article-title":"Clinimetric evaluation of the Simpson-Angus Scale in older adults with schizophrenia","volume":"34","author":"Blanchet","year":"2014","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2377-5-5","article-title":"Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population","volume":"5","author":"Janno","year":"2005","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jaac.2015.06.015_bib53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00213-002-1082-6","article-title":"Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol","volume":"162","author":"Tauscher","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jaac.2015.06.015_bib54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.21854","article-title":"Failure of recognition of drug-induced parkinsonism in the elderly","volume":"23","author":"Esper","year":"2008","journal-title":"Move Disord"},{"key":"10.1016\/j.jaac.2015.06.015_bib55","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/schbul\/sbn146","article-title":"Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis","volume":"36","author":"Koning","year":"2010","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2015.06.015_bib56","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1089\/cap.2006.0055","article-title":"Methylphenidate-induced orofacial and extremity dyskinesia","volume":"17","author":"Balazs","year":"2007","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib57","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/cap.2006.0117","article-title":"One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review","volume":"17","author":"Correll","year":"2007","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2015.06.015_bib58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00131746-200701000-00003","article-title":"EPS profiles: the atypical antipsychotics are not all the same","volume":"13","author":"Weiden","year":"2007","journal-title":"J\u00a0Psychiatr Pract"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856715003986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856715003986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T02:58:14Z","timestamp":1537498694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856715003986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0890856715003986"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2015.06.015","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}